PTI. The Hyderabad-based pharma major has tied up with Washington University School of Medicine in St Louis to develop novel "chimp-adenovirus" (Chimpanzee adenovirus), a single doseintranasalvaccine for COVID-19.
Dubbed as BBV154, the preclinical trial of its intranasal COVID-19 vaccine was already completed for toxicology, immunogenicity and challenge studies."These studies have been conducted in the USA and India.
Phase I human clinical trials will commence during Feb-March, 2021," Bharat Biotech told PTI. The trial will be be conducted in India, Bharat Biotech added.
It will be held in Saint Louis University's Vaccine and Treatment Evaluation Unit, according to the news agency."The drugmaker is focusing on the intranasal vaccine as the.